Danaher-GE BioPharma approved in South Korea, with bioprocessing divestment conditions
Danaher’s proposed acquisition of GE BioPharma has been cleared in South Korea, conditional on a divestment package. The Korea Fair Trade Commission has granted approval to Danaher’s $21.4 billion acquisition of the...To view the full article, register now.
Already a subscriber? Click here to view full article